Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study Meeting Abstract
| Authors: | Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Okamoto, I.; Inoue, T.; Cid, J. R. R.; Zhang, L.; Yang, C. T.; Jimenez, E. D. L. M.; Zhou, J.; Perol, M.; Lee, K. H.; Vicente, D.; Ichihara, E.; Riely, G. J.; Luo, Y.; Bhagwati, N. S.; Lu, S. |
| Abstract Title: | Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100036 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA9000 |
| Notes: | Meeting Abstract: LBA9000 -- Meeting was also available virtually -- Source: Wos |
